This study is looking into whether a drug called Maraviroc can help prevent a serious problem called Primary Graft Dysfunction (PGD) in people receiving a lung transplant. PGD is when the new lung doesn't work well right after surgery and is a major cause of early death. Researchers believe PGD is caused by certain immune cells, and Maraviroc is an FDA-approved drug that can block these cells. You might be able to join if you are 18 or older, are scheduled for a bilateral lung transplant, and have a high risk of PGD. The study will compare Maraviroc to a placebo (an inactive substance) to see if Maraviroc can reduce the number of severe PGD cases within three days after transplant. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 120 participants. It will compare Maraviroc to a placebo, which is an inactive substance that looks and tastes the same as Maraviroc.

What's involved

You would receive Maraviroc or placebo immediately before and for three days after your lung transplant surgery, totaling seven doses. You would also have physical exams and blood tests.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of the study, severe Primary Graft Dysfunction, is measured at 3 days after transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.